Trial Profile
A Phase I/II, Randomized, Double Blind, Placebo-controlled Clinical Study of IMM529 for the Treatment of Clostridium-difficile Infection (CDI).
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Jul 2023
Price :
$35
*
At a glance
- Drugs IMM 529 (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions; First in man
- Sponsors Immuron
- 30 Jun 2023 According to an Immuron Media Release, In the next twelve months the Company anticipates FDA submission of an IND for IMM-529 for Clostridioides difficile (CDI).
- 08 Oct 2021 Results published in the Media Release
- 01 Oct 2021 According to an Immuron media release, findings were published in the Journal Drug Development Research 2021.